7.2 C
London
Monday, November 18, 2024
HomeTagsLecanemab

Tag: Lecanemab

spot_imgspot_img

Japan – Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain

Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing...

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized...

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel

Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved in...

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong

Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody...

Japan – “LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea

Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble...

Japan – Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img